Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,145.03 -5.16 (-0.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?
Regeneron has fallen more than 6% over the past six weeks, and dropped again Thursday, as the DOJ focuses on its Eylea franchise. 
Via Investor's Business Daily
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
Via Benzinga
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Should You Sell This Stock Following a Regulatory Roadblock?
It's not the first such obstacle this high-performing drugmaker has faced. 
Via The Motley Fool
5 Healthcare Stocks to Buy for 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
Via Benzinga
Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
Via Benzinga
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
Via Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Exposures Product Safety
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense. 
Via The Motley Fool
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in Friday Morning Trading
Via Investor Brand Network
Regeneron Pharmaceuticals Unusual Options Activity For March 20
Via Benzinga
Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals
Via Benzinga
Decoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture?
Via Benzinga
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run. 
Via InvestorPlace
FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
The FDA issues complete response letters to Regeneron Pharmaceuticals Inc's BLA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, requesting more trial data... 
Via Benzinga
Exposures Product Safety
Regeneron Provides Update on Biologics License Application for Odronextamab
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
The market for weight loss drug stocks is massive, and these three companies could be the biggest beneficiaries of this trend. 
Via InvestorPlace
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in March 2024
These 3 undervalued biotech stocks have been left behind so far but things could begin to turn around as we head into March. 
Via InvestorPlace
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
$250,000 top award goes to Achyuta Rajaram in the nation’s oldest and most prestigious Science, Technology, Engineering and Math (STEM) competition for high school seniors 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH) 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be in store for all three of these drugmakers. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
2 Biotech Stocks to Buy Hand Over Fist in March
These stocks are worth buying in most months of the year. 
Via The Motley Fool
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising. 
Via InvestorPlace
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.